Compared with traditional de novo drug discovery, drug repurposing has become an
attractive drug discovery strategy due to its low-cost and high efficiency. Through a …

Simple Summary Multiple Myeloma (MM) is a hematologic malignancy caused by aberrant
plasma cell proliferation in the bone marrow (BM) and constitutes the second most common …

Big Data bring new opportunities to modern society and challenges to data scientists. On the
one hand, Big Data hold great promises for discovering subtle population patterns and …

Half a century ago, thalidomide was widely prescribed to pregnant women as a sedative but
was found to be teratogenic, causing multiple birth defects. Today, thalidomide is still used in …

Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell
malignancy, have dramatically improved. The development of the immunomodulatory drugs …

Immunomodulatory drugs (IMiDs) are thalidomide analogues, which possess pleiotropic anti-
myeloma properties including immune-modulation, anti-angiogenic, anti-inflammatory and …

BM mesenchymal stromal cells (BM-MSCs) support multiple myeloma (MM) cell growth, but
little is known about the putative mechanisms by which the BM microenvironment plays an …

Multiple myeloma is a plasma cell malignancy characterized by complex heterogeneous
cytogenetic abnormalities. The bone marrow microenvironment promotes multiple myeloma …

We provide an overview on soft-tissue extramedullary plasmacytomas (EMPs) in multiple
myeloma (MM). We reviewed the incidence of EMPs in MM, myeloma bone marrow homing …

Thalidomide was originally used to treat morning sickness, but was banned in the 1960s for
causing serious congenital birth defects. Remarkably, thalidomide was subsequently …